ACS Pharmacology & Translational Science · 2021 · 120 citations · 43 references
NursingPsychiatryPsychologyClinical PsychologyPsychotherapySubstance Use DisordersAddictionMental HealthMental IllnessPsychosocial InterventionsSpiritual ExperienceSpiritualityAnecdotal EvidenceEgo DissolutionMental Health BenefitsNative Mental HealthPsychiatric ManifestationsSelf-report Symptom ScalesTherapeutic Rituals
Mescaline is a naturally occurring psychoactive alkaloid that has been used as a sacrament by Indigenous populations in spiritual ritual and healing ceremonies for millennia. Despite promising early preliminary research and favorable anecdotal reports, there is limited research investigating mescaline’s psychotherapeutic potential. We administered an anonymous online questionnaire to adults (N = 452) reporting use of mescaline in naturalistic settings about mental health benefits attributed to mescaline. We assessed respondents’ self-reported improvements in depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD). Of the respondents reporting histories of these clinical conditions, most (68–86%) reported subjective improvement following their most memorable mescaline experience. Respondents who reported an improvement in their psychiatric conditions reported significantly higher ratings of acute psychological factors including mystical-type, psychological insight, and ego dissolution effects compared to those who did not report improvements (Cohen’s d range 0.7 – 1.5). Many respondents (35–50%) rated the mescaline experience as the single or top five most spiritually significant or meaningful experience(s) of their lives. Acute experiences of psychological insight during their mescaline experience were associated with increased odds of reporting improvement in depression, anxiety, AUD and DUD. Additional research is needed to corroborate these preliminary findings and to rigorously examine the efficacy of mescaline for psychiatric treatment in controlled, longitudinal clinical trials.
43
Roland R. Griffiths, Matthew W. Johnson, Michael A. Carducci et al. · Journal of Psychopharmacology · 2016 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +10
Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al. · Journal of Psychopharmacology · 2016 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +17
Drug harms in the UK: a multicriteria decision analysis
David Nutt, Leslie A. King, Lawrence D. Phillips · The Lancet · 2010 · 1.7K citations
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Alan K. Davis, Frederick S. Barrett, Darrick G. May et al. · JAMA Psychiatry · 2020 · 1.3K citations · Full text